Ignite Creation Date:
2025-12-24 @ 9:46 PM
Ignite Modification Date:
2026-01-02 @ 6:50 AM
Study NCT ID:
NCT07070232
Status:
RECRUITING
Last Update Posted:
2025-11-19
First Post:
2025-07-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'C564369', 'term': 'Lethal Congenital Contracture Syndrome 2'}, {'id': 'D008545', 'term': 'Melanoma'}, {'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D018326', 'term': 'Nevi and Melanomas'}, {'id': 'D012878', 'term': 'Skin Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D017964', 'term': 'Itraconazole'}, {'id': 'D017374', 'term': 'Paroxetine'}], 'ancestors': [{'id': 'D014230', 'term': 'Triazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D010879', 'term': 'Piperazines'}, {'id': 'D010880', 'term': 'Piperidines'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 550}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-08-12', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2030-02', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-18', 'studyFirstSubmitDate': '2025-07-03', 'studyFirstSubmitQcDate': '2025-07-15', 'lastUpdatePostDateStruct': {'date': '2025-11-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-07-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-05', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)', 'timeFrame': 'from first dose of investigational medicinal product (IMP) up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)', 'description': 'By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2).'}, {'measure': 'Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs', 'timeFrame': 'from first dose of IMP up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)', 'description': 'By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2)'}, {'measure': 'Parts 1 and 2 - All cohorts except Cohort 1F - Confirmed overall response rate (ORR)', 'timeFrame': 'from the time of initiation of the first dose of IMP to approximately 38 months (Part 1) and approximately 48 months (Part 2)', 'description': "Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) based on the investigator's assessment (per Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST v1.1\\]) is observed as best overall response. By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2)."}, {'measure': 'Part 2 - Occurrence of dose limiting toxicities (DLTs)', 'timeFrame': 'from the time of initiation of the first dose of IMP up to 21 days', 'description': 'During the DLT observation period.'}, {'measure': 'Part 1 - Cohort 1F (DDI) only - PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT326 and unconjugated payload', 'timeFrame': 'from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose', 'description': 'Evaluation of Cmax without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.'}, {'measure': 'Part 1 - Cohort 1F (DDI) only - PK assessment: Area under the curve (AUC) over the last 17-day dosing interval derived from serum concentrations of BNT326 and unconjugated payload', 'timeFrame': 'from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose', 'description': 'Evaluation of AUC over the last 17-day dosing interval without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.'}], 'secondaryOutcomes': [{'measure': 'Part 1 - Cohort 1F (DDI) only - Occurrence of TEAEs, TRAEs, TESAEs, and TRSAEs', 'timeFrame': 'from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP', 'description': 'By treatment, with and without itraconazole or paroxetine'}, {'measure': 'Part 1 - Cohort 1F (DDI) only - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs', 'timeFrame': 'from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP', 'description': 'By cohort and dose, with and without itraconazole or paroxetine'}, {'measure': 'Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for vital signs', 'timeFrame': 'from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP'}, {'measure': 'Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for clinical laboratory tests', 'timeFrame': 'from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP'}, {'measure': 'Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for cardiac function', 'timeFrame': 'from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP', 'description': 'Assessments comprise 12-lead electrocardiogram (ECG), echocardiography (ECHO) Multi-gated acquisition (MUGA) (scanning) and left ventricular ejection fraction (LVEF).'}, {'measure': 'Part 1 - Cohort 1F (DDI) only - Occurrence of clinically relevant changes from baseline for Eastern Cooperative Oncology Group performance status (ECOG PS)', 'timeFrame': 'from the time of initiation of the first dose of IMP to 42 days after the last dose of IMP', 'description': 'The ECOG PS grades are: 0 = Fully active, able to carry on all pre-disease performance without restriction, 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work, 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours, 3 = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours, 4 = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair, 5 = Dead.'}, {'measure': "Parts 1 and 2 - All cohorts - Progression-free survival (PFS) based on investigator's assessment", 'timeFrame': 'from the time of initiation of the first dose of IMP to approximately 38 months (Part 1) and approximately 48 months (Part 2)', 'description': 'Defined as the time from first dose of IMP to the first objective tumor progression (progressive disease \\[PD\\] per RECIST 1.1) or death from any cause, whichever occurs first. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI).'}, {'measure': 'Parts 1 and 2 - All cohorts - Depth of response (DpR)', 'timeFrame': 'from the time of initiation of the first dose of IMP to approximately 38 months (Part 1) and approximately 48 months (Part 2)', 'description': 'Defined as the maximum percent reduction from baseline in tumor size measured by sum of target lesion diameter. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI).'}, {'measure': 'Parts 1 and 2 - All cohorts - Disease control rate (DCR)', 'timeFrame': 'from the time of initiation of the first dose of IMP to approximately 38 months (Part 1) and approximately 48 months (Part 2)', 'description': "Defined as the proportion of participants with a confirmed CR, PR, or stable disease (per RECIST 1.1 based on the investigator's assessment) is observed as best overall response. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI)."}, {'measure': 'Parts 1 and 2 - All cohorts - Duration of response (DoR)', 'timeFrame': 'from the time of initiation of the first dose of IMP to approximately 38 months (Part 1) and approximately 48 months (Part 2)', 'description': "Defined as the time from first objective response (CR or PR per RECIST 1.1 based on the investigator's assessment) to first occurrence of objective tumor progression (PD per RECIST 1.1 based on the investigator's assessment) or death from any cause, whichever occurs first. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI)."}, {'measure': 'Parts 1 and 2 - All cohorts - Time to response (TTR)', 'timeFrame': 'from the time of initiation of the first dose of IMP to approximately 38 months (Part 1) and approximately 48 months (Part 2)', 'description': "Defined as the time from first dose of IMP to first objective response (CR or PR per RECIST 1.1 based on the investigator's assessment). By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI)."}, {'measure': 'Parts 1 and 2 - All cohorts - Overall survival (OS)', 'timeFrame': 'from the time of initiation of the first dose of IMP to approximately 38 months (Part 1) and approximately 48 months (Part 2)', 'description': 'Defined as the time from first dose of IMP to death from any cause. By cohort and combination treatment regimen (all cohorts except Cohort 1F, DDI) or by treatment regimen only (for Cohort 1F, DDI).'}, {'measure': 'Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Cmax derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload', 'timeFrame': 'from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2)', 'description': 'For applicable participants, if data permits. By cohort and combination treatment regimen.'}, {'measure': 'Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: AUC derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload', 'timeFrame': 'from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2)', 'description': 'For applicable participants, if data permits. By cohort and combination treatment regimen.'}, {'measure': 'Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload', 'timeFrame': 'from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2)', 'description': 'For applicable participants, if data permits. By cohort and combination treatment regimen.'}, {'measure': 'Parts 1 and 2 - All cohorts except Cohort 1F - PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT326 ADC, total anti-HER3 antibody component, and unconjugated payload', 'timeFrame': 'from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose (Part 1) and 90 days post last IMP dose (Part 2)', 'description': 'For applicable participants, if data permits. By cohort and combination treatment regimen.'}, {'measure': 'Parts 1 and 2 - All cohorts - Anti-drug antibody (ADA) prevalence and ADA incidence', 'timeFrame': 'up to 1 year from the last dose of IMP', 'description': 'For applicable participants. By cohort and combination treatment regimen (against BNT326 and/or BNT327, as applicable).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Combination with other investigational agents', 'Programmed death-ligand 1 (PD-L1)', 'Antibody-drug conjugate (ADC)', 'Human epidermal growth factor receptor 3 (HER3)', 'Programmed Death-1 (PD-1)', 'Programmed Death-1 monoclonal antibodies', 'Combination chemotherapy', 'Anti vascular endothelial growth factor-A (anti-VEGF-A)', 'Bispecific antibody', 'Immunotherapy', 'Dose optimization', 'Time to progression', 'Vascular endothelial growth factor (VEGF)', 'Cutaneous Melanoma', 'Rare melanoma', 'Actionable oncogenic alterations (AGA)-negative non-small cell lung cancer (NSCLC)', 'Epithelial growth factor receptor mutated (EGFRm) NSCLC'], 'conditions': ['Advanced Solid Tumor']}, 'descriptionModule': {'briefSummary': 'This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.', 'detailedDescription': "Both parts (Part 1 and Part 2) will start enrolling study participants independent of each other.\n\nIn Part 1, participants with histologically or cytologically confirmed advanced solid tumors will receive BNT326 monotherapy in the following cohorts:\n\n* Cohort 1A: Cutaneous melanoma (second-line or higher \\[2L+\\]).\n* Cohort 1B: Actionable oncogenic alterations (AGA)-negative non-small cell lung cancer (NSCLC) 2L+.\n* Cohort 1C: Epithelial growth factor receptor mutated (EGFRm) NSCLC 2L+.\n* Cohort 1D: Rare melanoma (acral/uveal/mucosal melanoma).\n* Cohort 1E: Other advanced solid tumors.\n* Cohort 1F (drug-drug interaction \\[DDI\\] Cohort): Advanced solid tumors.\n\nIn Part 2, BNT326 will be studied in combination with other immunotherapeutic agents. The first combination treatment will be BNT326 with BNT327. The following cohorts are planned:\n\n* Cohort 2A: Cutaneous melanoma 2L+.\n* Cohort 2B: Human epidermal growth factor receptor 2 (HER2)-negative breast cancer.\n\nParticipants in Cohorts 1A, 1B, and 1C will be randomized to one of two dose levels of BNT326 in a 1:1 ratio. The sponsor may choose to open a dose randomization cohort in Cohort 2A for further dose optimization after dose escalation. No randomization is planned for Cohorts 1D, 1E, 1F, and 2B.\n\nThe study will consist of a screening period, a treatment period, a safety follow-up period, an efficacy follow-up period, and a long-term survival follow-up period. Study treatment will be continued for up to 24 months or until disease progression, withdrawal of consent, termination of the study by the sponsor, or unacceptable toxicity. For each participant, the treatment and follow-up periods are projected to be completed within \\~38 months (Part 1) and \\~48 months (Part 2), unless participants are continuing to benefit from treatment per investigator's recommendation and upon sponsor approval."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Key Inclusion Criteria (applicable to all participants and all parts unless otherwise specified):\n\n* Aged ≥18 years at the time of giving informed consent.\n* Have histologic or cytologic documented advanced disease, either at relapse or upon diagnosis of metastatic disease. This requirement may be considered met when advanced disease derives from unequivocal progression of a previously biopsied site of disease (e.g., progression of residual tumor after concomitant chemo-radiation for Stage III NSCLC).\n* Have measurable disease defined by RECIST 1.1.\n* All participants must provide a tumor tissue sample (Formalin-fixed paraffin-embedded \\[FFPE\\] slides) from archival tissue. The archival tissue can be an FFPE block or freshly cut slides derived from the advanced setting or a new/fresh tumor biopsy.\n* Have ECOG performance status of 0 or 1.\n* Have adequate organ and bone marrow function within 7 days before randomization/enrollment.\n* Cohort 1A:\n\n * Have histologically or cytologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma not amenable to local therapy.\n * Participants must have previously received a PD-1 or PD-L1 inhibitor, and, for participants with human gene that encodes a protein called B-Raf (BRAF) gene mutant melanoma, a prior treatment regimen that included vemurafenib, dabrafenib, or another BRAF gene inhibitor with or without mitogen-activated protein kinase protein inhibitor, if available and clinically indicated per local standard of care (SoC) and have experienced progression during or after the previous treatment or discontinued from prior therapy due to intolerance.\n* Cohort 1B and 1C: Have advanced (i.e., metastatic or locally recurrent where local therapy with curative intent is not possible) non-squamous or squamous NSCLC.\n* Cohort 1B:\n\n * Have no actionable genomic alterations, such as EGFR mutations, anaplastic lymphoma kinase rearrangements, or other genomic alterations for which targeted molecular therapies are available. For enrolled participants with predominantly squamous histology tumors, molecular testing will not be required in cases where it is not part of the SoC.\n * Have experienced relapse or progression during or after treatment with standard systemic therapy including platinum-based chemotherapy and/or immune checkpoint inhibitor in the advanced/metastatic setting or discontinued from prior therapy due to intolerance.\n * Participants must have received 1 to 3 lines of systemic treatment, which can include anti-PD-1/PD-L1 therapy (if PD-L1 positive), chemotherapy, and anti-angiogenic agents. These treatments may be administered concurrently or sequentially. Prior chemotherapy must be limited to fewer than 2 lines.\n* Cohort 1C:\n\n * Have documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).\n * Participants must have received one or two prior lines of systemic therapy for advanced and/or metastatic disease, which must include treatment with an approved EGFR Tyrosine Kinase Inhibitors (TKI), with at least one being a third-generation EGFR TKI. If there is no third-generation EGFR TKI approved as part of SoC by local health authorities in a certain country, failure/progression on any EGFR TKI is acceptable for eligibility.\n * Participants receiving an EGFR TKI at the time of signing informed consent may continue to take the EGFR TKI until 5 days prior to Cycle 1 Day 1.\n * Chemotherapy is permitted only if it was administered in combination with an EGFR TKI as part of a single line of therapy and as the initial (first line) treatment for advanced/metastatic disease. Participants must not have received any other systemic therapies (such as chemotherapy, immunotherapy, or targeted agents) for advanced/metastatic disease, unless those treatments were given in combination with an EGFR TKI\n * Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.\n* Cohort 1D: Have histologically or cytologically confirmed diagnosis of unresectable or metastatic acral/uveal/mucosal melanoma not amenable to local therapy.\n* Cohort 1D: Participants must have:\n\n * Previously been treated with a PD-1 or PD-L1 inhibitor, if clinically indicated and available per local SoC, and/or\n * For participants with Human Leukocyte Antigen Alleles (HLA-A)\\*02:01 serotype-positive disease (only applicable for uveal melanoma), previously been treated with tebentafusp-tebn if clinically indicated and available per local SoC, and\n * Experienced progression during or after the previous treatment or discontinued from prior therapy due to intolerance.\n* Cohorts 1E and 1F (DDI): Have histologically or cytologically confirmed diagnosis of unresectable or metastatic advanced solid tumor not amenable to ablative or curative approach including, but not limited to:\n\n * Cholangiocarcinoma, including tumors of the intra- and extrahepatic biliary tract and gallbladder\n * Hepatocellular carcinoma (HCC).\n * Renal cell carcinoma\n * Endometrial carcinoma, excluding those classified as true sarcomas\n * Pancreatic ductal adenocarcinoma (PDAC) (see below other related inclusion criterion)\n * Neuroendocrine tumor of pancreatic, gastrointestinal, lung, and thymus that is well differentiated, Grade 1 to 3.\n* Cohort 1E and 1F (DDI): Have experienced disease progression on at least one and no more than three lines of prior therapy or, for Cohort 1E only, discontinued from prior therapy due to intolerance.\n* Cohort 1E and 1F (DDI): (For participants with PDAC only) Have received one or two lines of systemic therapy for metastatic tumors, and have experienced progression or intolerance to the treatment during or following therapy.\n* Cohort 2A: Have histologically or cytologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma not amenable to local therapy.\n* Cohort 2B: Have histologically or cytologically confirmed diagnosis of recurrent unresectable or metastatic breast cancer that is documented as HER2-negative and either hormone receptor (HR)-negative or HR-positive per American Society of Clinical Oncology/College of American Pathologists guidelines.\n\nKey Exclusion Criteria (applicable to all participants and all parts unless otherwise specified):\n\n* Have a history of intolerance to treatment with a topoisomerase I inhibitor or intolerance to an ADC that consists of a topoisomerase I inhibitor, including but not limited to topotecan, irinotecan, and deruxtecan (e.g., severe diarrhea).\n* Have an uncontrolled concomitant or intercurrent illness that contra-indicates study participation, limits compliance with study procedures or substantially increases the risk of incurring adverse events, including:\n\n * Bleeding diathesis or active hemorrhage,\n * Active infection,\n * Child-Pugh class B or C cirrhosis,\n * Pulmonary disease with significant impact in lung function\n * Oncologic emergencies or complications (e.g., malignant hypercalcemia, superior vena cava syndrome, carcinoid syndrome that is unstable and with available alternative therapies),\n * Psychiatric or abuse condition\n* Have LVEF \\<50% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization/enrollment.\n* Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization/enrollment.\n* Have a history of (non-infectious) interstitial lung disease (ILD) /pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Asymptomatic interstitial changes caused by previous radiation therapy, chemotherapy, or other factors such as smoking are acceptable.\n* Are a participant of child-bearing potential who are pregnant or breastfeeding or are planning pregnancy within 225 days (\\~7.5 months) after receiving last dose of BNT326 and within 6 months after last dose of BNT327, whichever is longer.\n* Are potentially fertile males, who are planning to father children during the study or within 135 days (\\~4.5 months) after the last dose of BNT326 and within 6 months after last dose of BNT327, whichever is longer.\n* Are subject to exclusion periods from another investigational study.\n* Participants with significant risks of hemorrhage or evidence of major coagulation disorders as specified in the protocol.\n* Cohort 1E: Have histological diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.'}, 'identificationModule': {'nctId': 'NCT07070232', 'briefTitle': 'A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors', 'organization': {'class': 'INDUSTRY', 'fullName': 'BioNTech SE'}, 'officialTitle': 'A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors', 'orgStudyIdInfo': {'id': 'BNT326-01'}, 'secondaryIdInfos': [{'id': '2024-517261-16-00', 'type': 'CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part 1 (Cohort 1A) - BNT326 monotherapy', 'description': 'BNT326 (dose level \\[DL1\\] or DL2)', 'interventionNames': ['Drug: BNT326']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1 (Cohort 1B) - BNT326 monotherapy', 'description': 'BNT326 (DL1 or DL2)', 'interventionNames': ['Drug: BNT326']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1 (Cohort 1C) - BNT326 monotherapy', 'description': 'BNT326 (DL1 or DL2)', 'interventionNames': ['Drug: BNT326']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1 (Cohort 1D) - BNT326 monotherapy', 'description': 'BNT326 (DL2)', 'interventionNames': ['Drug: BNT326']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1 (Cohort 1E) - BNT326 monotherapy', 'description': 'BNT326 (DL2)', 'interventionNames': ['Drug: BNT326']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1 (Cohort 1F, drug-drug interaction [DDI]) - BNT326 + itraconazole', 'description': 'BNT326 (DL1 or DL2) + itraconazole', 'interventionNames': ['Drug: BNT326', 'Drug: Itraconazole']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1 (Cohort 1F, DDI) - BNT326 + paroxetine', 'description': 'BNT326 (DL1 or DL2) + paroxetine', 'interventionNames': ['Drug: BNT326', 'Drug: Paroxetine']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2 (Cohort 2A) - BNT326 + BNT327', 'description': 'Combination therapy of BNT326 (DL1 or DL2) and BNT327 (DL1 or DL2) Optionally, combinations with lower doses of BNT326 and/or BNT327 may be explored.', 'interventionNames': ['Drug: BNT326', 'Drug: BNT327']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2 (Cohort 2B) - BNT326 + BNT327', 'description': 'Combination therapy of BNT326 (DL1 or DL2) and BNT327 (DL1 or DL2) Optionally, combinations with lower doses of BNT326 and/or BNT327 may be explored.', 'interventionNames': ['Drug: BNT326', 'Drug: BNT327']}], 'interventions': [{'name': 'BNT326', 'type': 'DRUG', 'description': 'Intravenous (IV) infusion', 'armGroupLabels': ['Part 1 (Cohort 1A) - BNT326 monotherapy', 'Part 1 (Cohort 1B) - BNT326 monotherapy', 'Part 1 (Cohort 1C) - BNT326 monotherapy', 'Part 1 (Cohort 1D) - BNT326 monotherapy', 'Part 1 (Cohort 1E) - BNT326 monotherapy', 'Part 1 (Cohort 1F, DDI) - BNT326 + paroxetine', 'Part 1 (Cohort 1F, drug-drug interaction [DDI]) - BNT326 + itraconazole', 'Part 2 (Cohort 2A) - BNT326 + BNT327', 'Part 2 (Cohort 2B) - BNT326 + BNT327']}, {'name': 'BNT327', 'type': 'DRUG', 'description': 'IV infusion', 'armGroupLabels': ['Part 2 (Cohort 2A) - BNT326 + BNT327', 'Part 2 (Cohort 2B) - BNT326 + BNT327']}, {'name': 'Itraconazole', 'type': 'DRUG', 'description': 'Oral administration', 'armGroupLabels': ['Part 1 (Cohort 1F, drug-drug interaction [DDI]) - BNT326 + itraconazole']}, {'name': 'Paroxetine', 'type': 'DRUG', 'description': 'Oral administration', 'armGroupLabels': ['Part 1 (Cohort 1F, DDI) - BNT326 + paroxetine']}]}, 'contactsLocationsModule': {'locations': [{'zip': '34232', 'city': 'Sarasota', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Florida Cancer Specialists', 'geoPoint': {'lat': 27.33643, 'lon': -82.53065}}, {'zip': '49546', 'city': 'Grand Rapids', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'START Midwest, LLC', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Hospital', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'facility': 'The University of Texas MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'South Texas Accelerated Research Therapeutics (START), LLC', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '84119', 'city': 'West Valley City', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'START Mountain Region', 'geoPoint': {'lat': 40.69161, 'lon': -112.00105}}, {'zip': '5000', 'city': 'Adelaide', 'state': 'South Australia', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Cancer Research SA', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'zip': '6009', 'city': 'Nedlands', 'state': 'Western Australia', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'One Clinical Research Pty Ltd', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'zip': 'B15 2TH', 'city': 'Birmingham', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'facility': 'Queen Elizabeth Hospital', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'CF14 2TL', 'city': 'Cardiff', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'facility': 'Velindre Cancer Centre', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'zip': 'L7 8YA', 'city': 'Liverpool', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'facility': 'The Clatterbridge Cancer Centre', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'NW3 2QG', 'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Royal Free Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SW3 6JJ', 'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Royal Marsden Hospital-London', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'W12 0HS', 'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Imperial College London', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'W1T 7HA', 'city': 'London', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'facility': 'University College London Hospitals', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M20 4BX', 'city': 'Manchester', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'The Christie Hospital', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'NE7 7DN', 'city': 'Newcastle upon Tyne', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'facility': 'Northern Centre for Cancer Care', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}, {'zip': 'SM2 5PT', 'city': 'Sutton', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Royal Marsden Hospital', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}], 'centralContacts': [{'name': 'BioNTech clinical trials patient information', 'role': 'CONTACT', 'email': 'patients@biontech.de', 'phone': '+49 6131 9084', 'phoneExt': '0'}], 'overallOfficials': [{'name': 'BioNTech Responsible Person', 'role': 'STUDY_DIRECTOR', 'affiliation': 'BioNTech SE'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'BioNTech SE', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}